Challenges in schizoaffetive disorder therapeutic – a case report of a patient with hiperprolactinemia

INTRODUCTION: The only FDA approval therapeutic for schizoaffective disorder is paliperidone. Hiperprolactinemia is one of the most frequent side effects induced by first generation antipsychotics (FGA) or by second generation antipsychotic (SGA), such as risperidone and paliperidone. Prolactin rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, D., Jeremias, D., Laginhas, C., Sequeira, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480387/
http://dx.doi.org/10.1192/j.eurpsy.2021.2107

Ejemplares similares

Ejemplares similares